

Ensifentrine

Chemical Properties


CAS No. : 1884461-72-6

Formula: C₂₆H₃₁N₅O₄

Molecular Weight: 477.56

Storage: Keep away from moisture, Store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



Biological Description

Description	Ensifentrine (Ensifentrinum) is a PDE3/4 inhibitor, although its affinity for PDE3 (IC ₅₀ : 0.4 nM) is 3,440 times higher than that for PDE4 (IC ₅₀ : 1479 nM), that is under clinical development for the treatment of asthma and COPD and, potentially, cystic fibrosis.
Targets (IC ₅₀)	PDE
In vitro	Electrical field stimulation-induced contraction of guinea pig superfused isolated tracheal preparations was significantly inhibited by Ensifentrine (10 microM) (percentage control; 93 +/- 1.2). Contractile responses were suppressed for up to 12 h after termination of superfusion with Ensifentrine demonstrating a long duration of action. Ensifentrine inhibited, in a concentration-dependent manner, lipopolysaccharide-induced tumor necrosis factor alpha release from human monocytes [IC ₅₀ ; 0.52 microM (0.38-0.69)] and proliferation of human mononuclear cells to phytohemagglutinin [IC ₅₀ ; 0.46 microM (0.24-0.9)][2].
In vivo	Ensifentrine administered orally significantly inhibited eosinophil recruitment following antigen challenge in ovalbumin-sensitized guinea pigs. Likewise, inhalation of dry powder containing Ensifentrine by conscious guinea pigs (25% in micronized lactose) 1.5 h before antigen exposure significantly inhibited the recruitment of eosinophils to the airways. Exposure of conscious guinea pigs to inhalation of dry powder containing Ensifentrine (2.5%) and RPL565 (25%) in micronized lactose significantly inhibited histamine-induced plasma protein extravasation in the trachea and histamine-induced bronchoconstriction over a 5.5-h period[2].

Solubility Information

Solubility	DMSO: 16.33 mg/mL (34.19 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (2.09 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.094 mL	10.4699 mL	20.9398 mL
5 mM	0.4188 mL	2.094 mL	4.188 mL
10 mM	0.2094 mL	1.047 mL	2.094 mL
50 mM	0.0419 mL	0.2094 mL	0.4188 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Henrik Watz, et al. Symptom Improvement Following Treatment with the Inhaled Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine in Patients with Moderate to Severe COPD - A Detailed Analysis. *Int J Chron Obstruct Pulmon Dis.* 2020 Sep 16;15:2199-2206.

Victoria Boswell-Smith, et al. The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-a]isoquinolin-4-one]. *J Pharmacol Exp Ther.* 2006 Aug;318(2):840-8.

Cazzola M, et al. Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD. *Expert Opin Investig Drugs.* 2019 Oct;28(10):827-833.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481